# NRX Pharmaceuticals, Inc.: filings

NRXP · Nasdaq · CIK 1719406 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/nrxp.md) · [Financials](/companies/nrxp/financials.md) · [Filings](/companies/nrxp/filings.md) · [Insiders](/companies/nrxp/insiders.md)

## Reports and events: 211 filings

Newest first, by EDGAR acceptance time (Eastern). Filter with ?form= one of: `periodic`, `8-K`, `10-K`, `10-Q`, `4`, `proxy`, `13dg`, `all`, or any form this company filed (8-K 131, 4 47, 424B3 44, 3 30, 10-Q 26, 424B5 15, CORRESP 15, DEF 14A 13, UPLOAD 12, PRE 14A 11, 425 10, EFFECT 10, SC 13G/A 10, 10-K 9, SC 13G 8, DEFA14A 7, 10-K/A 6, 8-K/A 5, S-1 5, S-4/A 5, SC 13D 5, SC 13D/A 5, 4/A 4, S-1/A 4, 25-NSE 3, POS AM 3, 10-Q/A 2, ARS 2, D 2, NT 10-Q 2, POS EX 2, S-3 2, S-3/A 2, SCHEDULE 13G 2, SCHEDULE 13G/A 2, SEC STAFF LETTER 2, 424B4 1, 424B7 1, 5 1, 8-A12B 1, CERTNAS 1, NT 10-K 1, PRER14A 1, RW 1, S-1MEF 1, S-4 1, S-8 1).

| Filed | Accepted | Form | What it is | Accession |
| --- | --- | --- | --- | --- |
| 2026-10-16 | 21:16 ET | [8-K](/filings/0001437749-26-032828.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001437749-26-032828 |
| 2026-10-05 | 21:00 ET | [8-K](/filings/0001437749-26-032042.md) | 1.01 Entry into a material agreement; 9.01 Financial statements and exhibits | 0001437749-26-032042 |
| 2026-09-16 | 01:17 ET | [8-K](/filings/0001437749-26-030492.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001437749-26-030492 |
| 2026-09-14 | 12:00 ET | [8-K](/filings/0001437749-26-030228.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001437749-26-030228 |
| 2026-08-17 | 12:00 ET | [8-K](/filings/0001437749-26-028111.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001437749-26-028111 |
| 2026-08-14 | 20:32 ET | [10-Q](/filings/0001437749-26-028027.md) | Quarterly report, period 2026-06-30 | 0001437749-26-028027 |
| 2026-08-07 | 11:00 ET | [8-K](/filings/0001437749-26-026428.md) | 7.01 Regulation FD disclosure | 0001437749-26-026428 |
| 2026-07-22 | 11:00 ET | [8-K](/filings/0001437749-26-024037.md) | 8.01 Other events | 0001437749-26-024037 |
| 2026-06-04 | 21:20 ET | [8-K](/filings/0001437749-26-019576.md) | 1.01 Entry into a material agreement; 8.01 Other events; 9.01 Financial statements and exhibits | 0001437749-26-019576 |
| 2026-06-02 | 21:30 ET | [8-K](/filings/0001437749-26-019196.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001437749-26-019196 |
| 2026-05-15 | 20:30 ET | [10-Q](/filings/0001437749-26-017397.md) | Quarterly report, period 2026-03-31 | 0001437749-26-017397 |
| 2026-03-24 | 20:32 ET | [8-K](/filings/0001437749-26-009611.md) | 5.02 Departure or appointment of officers or directors; 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0001437749-26-009611 |
| 2026-03-23 | 20:30 ET | [10-K](/filings/0001437749-26-009418.md) | Annual report, period 2025-12-31 | 0001437749-26-009418 |
| 2026-02-23 | 22:00 ET | [DEF 14A](/filings/0001437749-26-005119.md) | Proxy statement, period 2026-03-23 | 0001437749-26-005119 |
| 2026-02-17 | 14:21 ET | [8-K](/filings/0001437749-26-004246.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001437749-26-004246 |
| 2026-02-17 | 14:20 ET | [8-K](/filings/0001437749-26-004245.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001437749-26-004245 |
| 2026-02-02 | 22:16 ET | [8-K](/filings/0001437749-26-002682.md) | 5.02 Departure or appointment of officers or directors | 0001437749-26-002682 |
| 2026-01-16 | 22:09 ET | [8-K](/filings/0001437749-26-001455.md) | 3.01 Delisting notice; 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001437749-26-001455 |
| 2025-12-29 | 21:30 ET | [8-K](/filings/0001437749-25-038835.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001437749-25-038835 |
| 2025-11-26 | 21:31 ET | [8-K](/filings/0001437749-25-036452.md) | 4.01 Change of auditor; 9.01 Financial statements and exhibits | 0001437749-25-036452 |
| 2025-11-21 | 21:32 ET | [8-K/A](/filings/0001437749-25-036005.md) | 9.01 Financial statements and exhibits | 0001437749-25-036005 |
| 2025-11-14 | 21:32 ET | [10-Q](/filings/0001437749-25-035210.md) | Quarterly report, period 2025-09-30 | 0001437749-25-035210 |
| 2025-10-23 | 20:31 ET | [8-K](/filings/0001437749-25-031637.md) | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001437749-25-031637 |
| 2025-09-26 | 12:01 ET | [8-K](/filings/0001437749-25-029907.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001437749-25-029907 |
| 2025-09-12 | 20:33 ET | [8-K](/filings/0001437749-25-028949.md) | 2.01 Completion of an acquisition or disposition; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001437749-25-028949 |
| 2025-09-08 | 20:32 ET | [8-K](/filings/0001437749-25-028567.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001437749-25-028567 |
| 2025-08-18 | 20:31 ET | [8-K](/filings/0001437749-25-027256.md) | 1.01 Entry into a material agreement; 2.02 Results of operations; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001437749-25-027256 |
| 2025-08-18 | 10:07 ET | [10-Q](/filings/0001437749-25-027167.md) | Quarterly report, period 2025-06-30 | 0001437749-25-027167 |
| 2025-08-15 | 01:47 ET | [8-K](/filings/0001437749-25-027059.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001437749-25-027059 |
| 2025-06-09 | 16:16 ET | [8-K](/filings/0001437749-25-019803.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001437749-25-019803 |
| 2025-05-21 | 20:38 ET | [8-K](/filings/0001437749-25-018000.md) | 2.02 Results of operations; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001437749-25-018000 |
| 2025-05-15 | 21:01 ET | [10-Q](/filings/0001437749-25-017252.md) | Quarterly report, period 2025-03-31 | 0001437749-25-017252 |
| 2025-05-13 | 12:30 ET | [8-K](/filings/0001437749-25-016272.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001437749-25-016272 |
| 2025-04-30 | 20:33 ET | [10-K/A](/filings/0001437749-25-013874.md) | Annual report, amended, period 2024-12-31 | 0001437749-25-013874 |
| 2025-04-17 | 21:24 ET | [8-K](/filings/0001437749-25-012303.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001437749-25-012303 |
| 2025-03-21 | 21:21 ET | [8-K](/filings/0001437749-25-008777.md) | 2.02 Results of operations; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001437749-25-008777 |
| 2025-03-14 | 20:31 ET | [10-K](/filings/0001437749-25-007743.md) | Annual report, period 2024-12-31 | 0001437749-25-007743 |
| 2025-02-03 | 21:40 ET | [8-K](/filings/0001437749-25-002610.md) | 1.01 Entry into a material agreement; 8.01 Other events; 9.01 Financial statements and exhibits | 0001437749-25-002610 |
| 2025-01-29 | 22:10 ET | [8-K](/filings/0001437749-25-002160.md) | 1.01 Entry into a material agreement; 2.03 New direct financial obligation; 3.02 Unregistered sale of equity; 8.01 Other events; 9.01 Financial statements and exhibits | 0001437749-25-002160 |
| 2025-01-22 | 21:32 ET | [8-K](/filings/0001437749-25-001569.md) | 5.02 Departure or appointment of officers or directors; 8.01 Other events; 9.01 Financial statements and exhibits | 0001437749-25-001569 |
| 2025-01-14 | 21:12 ET | [8-K](/filings/0001437749-25-001113.md) | 5.02 Departure or appointment of officers or directors; 8.01 Other events | 0001437749-25-001113 |
| 2025-01-10 | 13:32 ET | [8-K](/filings/0001437749-25-000801.md) | 1.01 Entry into a material agreement; 3.02 Unregistered sale of equity; 8.01 Other events; 9.01 Financial statements and exhibits | 0001437749-25-000801 |
| 2024-11-20 | 14:00 ET | [8-K](/filings/0001437749-24-035806.md) | 1.01 Entry into a material agreement; 5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits | 0001437749-24-035806 |
| 2024-11-15 | 22:24 ET | [8-K](/filings/0001437749-24-035521.md) | 2.02 Results of operations; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001437749-24-035521 |
| 2024-11-14 | 21:01 ET | [10-Q](/filings/0001437749-24-035289.md) | Quarterly report, period 2024-09-30 | 0001437749-24-035289 |
| 2024-11-14 | 17:21 ET | [S-1](/filings/0001437749-24-035167.md) | Registration statement | 0001437749-24-035167 |
| 2024-10-31 | 12:00 ET | [8-K](/filings/0001437749-24-032705.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001437749-24-032705 |
| 2024-10-15 | 20:52 ET | [8-K](/filings/0001437749-24-031268.md) | 1.01 Entry into a material agreement; 2.03 New direct financial obligation; 3.02 Unregistered sale of equity; 9.01 Financial statements and exhibits | 0001437749-24-031268 |
| 2024-10-11 | 20:53 ET | [8-K](/filings/0001437749-24-031133.md) | 5.02 Departure or appointment of officers or directors; 5.07 Shareholder vote results; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001437749-24-031133 |
| 2024-09-05 | 20:18 ET | [DEF 14A](/filings/0001437749-24-028549.md) | Proxy statement, period 2024-10-08 | 0001437749-24-028549 |

Page 1 of 5. [Older](/companies/nrxp/filings.md?page=2)
Source: SEC EDGAR, the company’s filing index. Last ingested by Listed: Oct 24, 2026, 15:15 ET. No prices; not investment advice.